{"id":"https://openalex.org/W2017976226","doi":"https://doi.org/10.1158/1535-7163.targ-11-b131","title":"Abstract B131: Modeling the evolution of resistance to RAF inhibitors in clinically relevant melanoma models.","display_name":"Abstract B131: Modeling the evolution of resistance to RAF inhibitors in clinically relevant melanoma models.","publication_year":2011,"publication_date":"2011-11-01","ids":{"openalex":"https://openalex.org/W2017976226","doi":"https://doi.org/10.1158/1535-7163.targ-11-b131","mag":"2017976226"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-11-b131","doi":"https://doi.org/10.1158/1535-7163.targ-11-b131","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-11-b131","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061132840","display_name":"Meghna Das Thakur","orcid":"https://orcid.org/0000-0003-2177-7401","observed_orcids":["https://orcid.org/0000-0003-2177-7401"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Meghna Das Thakur","raw_affiliation_strings":["1Novartis Institutes for Biomedical Research, Emeryville, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Novartis Institutes for Biomedical Research, Emeryville, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030991521","display_name":"Fernando Salangsang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fernando Salangsang","raw_affiliation_strings":["1Novartis Institutes for Biomedical Research, Emeryville, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Novartis Institutes for Biomedical Research, Emeryville, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042175121","display_name":"Nancy Pryer","orcid":"https://orcid.org/0000-0002-0149-1572","observed_orcids":["https://orcid.org/0000-0002-0149-1572"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nancy Pryer","raw_affiliation_strings":["1Novartis Institutes for Biomedical Research, Emeryville, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Novartis Institutes for Biomedical Research, Emeryville, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003652463","display_name":"Martin McMahon","orcid":"https://orcid.org/0000-0003-2812-1042","observed_orcids":["https://orcid.org/0000-0003-2812-1042"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin McMahon","raw_affiliation_strings":["2University of California, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of California, San Francisco, CA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049772515","display_name":"Darrin D. Stuart","orcid":"https://orcid.org/0000-0002-4666-4000","observed_orcids":["https://orcid.org/0000-0002-4666-4000"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Darrin Stuart","raw_affiliation_strings":["1Novartis Institutes for Biomedical Research, Emeryville, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Novartis Institutes for Biomedical Research, Emeryville, CA;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"11_Supplement","first_page":"B131","last_page":"B131"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.843999981880188},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.9139999747276306},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9869999885559082},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.9639999866485596},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7149999737739563},{"id":"https://openalex.org/keywords/raf-mek-erk-pathway","display_name":"Raf/MEK/ERK pathway","score":0.925000011920929},{"id":"https://openalex.org/keywords/tumor-heterogeneity","display_name":"tumor heterogeneity","score":0.843999981880188},{"id":"https://openalex.org/keywords/dose-scheduling","display_name":"dose scheduling","score":0.42399999499320984},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.546999990940094},{"id":"https://openalex.org/keywords/tumor-progression","display_name":"tumor progression","score":0.3449999988079071},{"id":"https://openalex.org/keywords/drug-withdrawal","display_name":"drug withdrawal","score":0.4440000057220459},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.5899999737739563},{"id":"https://openalex.org/keywords/dose-de-escalation","display_name":"dose de-escalation","score":0.5879999995231628}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.9222593307495117},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7624940276145935},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6231809258460999},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6130627989768982},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5632873773574829},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5140936970710754},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5139884352684021},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.49529901146888733},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.46676915884017944},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4316471219062805},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4300363063812256},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.42443668842315674},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.4235004186630249},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4205942451953888},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3505358099937439},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.3405863046646118},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29742172360420227},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2494267225265503},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.2002740502357483},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-11-b131","doi":"https://doi.org/10.1158/1535-7163.targ-11-b131","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-11-b131","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2038394683","https://openalex.org/W2062258918","https://openalex.org/W2056327493","https://openalex.org/W2058390096","https://openalex.org/W2171108516","https://openalex.org/W4237979552","https://openalex.org/W1535534078","https://openalex.org/W2398854768","https://openalex.org/W2016614429","https://openalex.org/W2000876153"],"abstract_inverted_index":{"Abstract":[0],"Activating":[1],"mutations":[2],"in":[3,14,44,54,56,62,124,138,146,157,179,209,222,266,275,402,412],"BRAF":[4],"kinase":[5],"are":[6,233,341],"one":[7],"of":[8,20,40,101,144,160,182,188,217,228,242,257,272,280,293,301,334,405,420,430],"the":[9,65,75,80,99,139,150,180,186,201,213,226,291,299,324,347,385,398,403,418,431],"most":[10],"common":[11],"genetic":[12,132,240],"alterations":[13],"human":[15,112],"melanoma,":[16,45],"with":[17,165,323,364],"over":[18,185],"50%":[19],"tumors":[21,184,198,244,308,340,370],"expressing":[22],"BRAFV600E.":[23],"Small":[24],"molecule":[25],"RAF":[26],"inhibitors":[27],"such":[28],"as":[29,46,72,268,270],"vemurafenib":[30],"have":[31,106,409],"demonstrated":[32],"proof-of-concept":[33],"that":[34,82,200,250,297,339,384],"BRAFV600E":[35,273],"is":[36,204,219,245,330],"a":[37,128,168,311,331,390],"key":[38],"driver":[39],"proliferation":[41],"and":[42,51,134,215,231,255,290,338,407,437],"survival":[43,53],"evidenced":[47],"by":[48,153,207,318,358,379],"tumor":[49,66,120,281,287,315,319,335,391],"regression":[50],"prolonged":[52],"patients":[55,64],"late":[57],"stage":[58],"clinical":[59,140,151],"trials.":[60],"Unfortunately,":[61],"many":[63],"response":[67,282],"can":[68],"be":[69,87,264],"quite":[70],"short-lived":[71],"resistance":[73,85,102,145],"to":[74,89,103,118,190,261,304,310,343,346,376,416],"inhibitor":[76],"rapidly":[77,344],"develops.":[78],"Understanding":[79],"mechanisms":[81],"underlie":[83],"drug":[84,155,302,360,368,406],"will":[86],"critical":[88],"providing":[90],"improved":[91],"treatment":[92,361],"options":[93],"for":[94,354,373],"these":[95,161],"patients.":[96,158],"To":[97],"model":[98],"emergence":[100,419],"vemurafenib,":[104],"we":[105],"established":[107],"an":[108],"early":[109],"passage":[110],"primary":[111,162],"melanoma":[113,163],"xenograft":[114],"model.":[115,277],"In":[116],"contrast":[117],"using":[119],"cell":[121,288,336,392],"lines,":[122],"this":[123,276,327,355],"vivo":[125,147],"system":[126],"recapitulates":[127],"more":[129],"appropriate":[130],"microenvironment,":[131],"diversity,":[133],"selective":[135,348,395],"pressure":[136,349,396],"observed":[137],"setting.":[141],"The":[142],"selection":[143],"also":[148],"reflects":[149],"setting":[152],"modeling":[154],"pharmacokinetics":[156],"Treatment":[159],"xenogafts":[164],"vemurafinib":[166,208],"on":[167],"long":[169],"term":[170],"continuous":[171],"dosing":[172],"regimen":[173],"at":[174],"clinically":[175],"relevant":[176],"doses":[177],"resulted":[178],"appearance":[181],"resistant":[183,210,237,243,307,365],"course":[187],"4":[189],"6":[191],"weeks.":[192],"Pharmacodynamic":[193],"(PD)":[194],"analysis":[195,241],"within":[196,389],"individual":[197],"indicated":[199],"RAF-MEK-ERK":[202],"pathway":[203,229],"still":[205],"suppressed":[206],"tumors,":[211],"although":[212],"degree":[214],"duration":[216],"suppression":[218],"less":[220,400],"than":[221],"sensitive":[223],"tumors.":[224,366],"Furthermore,":[225],"kinetics":[227],"inhibition":[230],"recovery":[232],"different":[234],"between":[235],"each":[236],"tumor.":[238],"While":[239],"ongoing,":[246],"biochemical":[247],"analyses":[248],"indicate":[249,383],"receptor":[251],"tyrosine":[252],"kinases":[253],"(RTK)":[254],"modulation":[256],"negative":[258],"feedback":[259],"loops":[260],"RTK":[262],"may":[263],"involved":[265],"resistance,":[267],"well":[269],"up-regulation":[271],"expression":[274],"Pharmacological":[278],"evaluation":[279],"has":[283],"provided":[284],"insight":[285],"into":[286],"populations":[289],"evolution":[292],"resistance.":[294,421],"We":[295],"find":[296],"increasing":[298],"dose":[300,414],"administered":[303],"mice":[305,363],"bearing":[306],"leads":[309],"significant":[312,410],"yet":[313],"transient":[314],"response,":[316],"followed":[317,378],"progression.":[320],"Taken":[321],"together":[322],"PD":[325],"data,":[326],"suggests":[328],"there":[329],"great":[332],"deal":[333],"heterogeneity,":[337],"able":[342],"adapt":[345],"being":[350],"applied.":[351],"Further":[352],"support":[353],"was":[356],"obtained":[357],"suspending":[359],"from":[362],"Upon":[367],"withdrawal,":[369],"initially":[371],"regressed":[372],"several":[374],"days":[375],"weeks,":[377],"re-growth.":[380],"These":[381],"data":[382],"adaptation":[386],"which":[387],"occurs":[388],"population":[393],"under":[394],"make":[397],"cells":[399],"fit":[401],"absence":[404],"could":[408],"implications":[411],"optimizing":[413],"schedules":[415],"prevent":[417],"Citation":[422],"Format:":[423],"{Authors}.":[424],"{Abstract":[425],"title}":[426],"[abstract].":[427],"In:":[428],"Proceedings":[429],"AACR-NCI-EORTC":[432],"International":[433],"Conference:":[434],"Molecular":[435],"Targets":[436],"Cancer":[438,450],"Therapeutics;":[439],"2011":[440],"Nov":[441],"12-16;":[442],"San":[443],"Francisco,":[444],"CA.":[445],"Philadelphia":[446],"(PA):":[447],"AACR;":[448],"Mol":[449],"Ther":[451],"2011;10(11":[452],"Suppl):Abstract":[453],"nr":[454],"B131.":[455]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}